iBio’s technology stack delivers precision antibodies designed to minimize downstream development risk through AI-guided epitope steering and optimization of monoclonal and next-gen CD3 T-cell engager bispecific antibodies. Our team of AI and machine-learning scientists, along with our drug hunters, are engineering antibodies for hard-to-drug targets, primarily in immunotherapy for cancer. We have a pipeline of 7 immuno-oncology therapeutics and a therapeutic candidate with the potential to treat various autoimmune diseases. Driven by our commitment to innovation, we are actively developing select programs internally while maintaining the flexibility to explore collaborative opportunities through licensing our programs to strategic partners.
We have one additional candidate available for partnering – IBIO-400 for Classical Swine Fever.
We are excited about the potential therapeutic benefits of our proprietary pipeline and are looking for partners who share our passion for bringing innovative treatments to advance healthcare and improve patient lives.
To learn more about our pipeline candidates and potential partnership opportunities, please contact us.